Realta Investment Advisors Makes New $1.16 Million Investment in Amgen Inc. $AMGN

Realta Investment Advisors purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 3,298 shares of the medical research company’s stock, valued at approximately $1,160,000.

A number of other hedge funds have also made changes to their positions in the stock. Anfield Capital Management LLC lifted its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC grew its holdings in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in Amgen during the fourth quarter valued at approximately $26,000. Tower View Wealth Management LLC grew its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares during the last quarter. Finally, Manning & Napier Advisors LLC raised its position in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Up 1.6%

Shares of AMGN stock opened at $358.61 on Friday. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market cap of $193.54 billion, a PE ratio of 24.96, a price-to-earnings-growth ratio of 3.60 and a beta of 0.42. The stock has a 50 day moving average of $340.70 and a 200-day moving average of $346.20.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter last year, the company posted $4.90 earnings per share. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts predict that Amgen Inc. will post 22.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on AMGN shares. Piper Sandler restated an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. Truist Financial lifted their target price on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Jefferies Financial Group initiated coverage on shares of Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. Leerink Partners reissued a “market perform” rating and set a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Finally, Guggenheim decreased their price target on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $354.42.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.